NeuroMetrix (NURO) 10-Q 20 Oct 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Oct. 19, 2022
Document Information [Line Items]
Entity Central Index Key	0001289850
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		7,757,226
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Type	10-Q
Entity Current Reporting Status	Yes
Entity Small Business	true
Entity Interactive Data Current	Yes
Security Exchange Name	NASDAQ
Trading Symbol	NURO
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-33351
Entity Registrant Name	NEUROMETRIX, INC.
Entity Incorporation, State or Country Code	DE
Entity Address, Postal Zip Code	01801
Local Phone Number	890-9989
Entity Filer Category	Non-accelerated Filer
Entity Tax Identification Number	04-3308180
Entity Address, Address Line One	4B Gill Street
Entity Address, City or Town	Woburn
Entity Address, State or Province	MA
City Area Code	781
Title of 12(b) Security	Common Stock, $0.0001 par value per share

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,772,005	$ 22,572,104
Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss	19,054,654	0
Accounts receivable, net	702,459	310,818
Inventories	1,057,239	706,553
Prepaid expenses and other current assets	845,649	598,384
Total current assets	23,432,006	24,187,859
Fixed assets, net	175,840	198,703
Operating Lease, Right-of-Use Asset	398,144	475,230
Other Assets, Noncurrent	26,400	26,400
Total assets	24,032,390	24,888,192
Current liabilities:
Accounts payable	539,379	284,036
Accrued expenses and compensation	1,134,659	814,155
Accrued Sales Return provisions	10,000	39,000
Operating Lease, Liability, Current	148,391	228,506
Total current liabilities	1,832,429	1,365,697
Operating Lease, Liability, Noncurrent	233,693	306,709
Total liabilities	2,066,122	1,672,406
Commitments and contingencies
Stockholders’ equity:
Common Stock, Value, Issued	714	669
Additional paid-in capital	224,853,549	222,378,373
Accumulated deficit	(202,887,996)	(199,163,257)
Total stockholders’ equity	21,966,268	23,215,786
Total liabilities and stockholders’ equity	$ 24,032,390	$ 24,888,192
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	25,000,000	25,000,000
Common Stock, Shares, Issued	7,137,519	6,694,296
Common Stock, Shares, Outstanding	7,137,519	6,694,296
Convertible preferred stock
Stockholders’ equity:
Preferred stock	$ 1	$ 1
Preferred Non-Convertible Stock
Stockholders’ equity:
Preferred stock	$ 0	$ 0

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from Contract with Customer, Including Assessed Tax	$ 1,968,003	$ 2,064,359	$ 6,408,695	$ 6,433,330
Other Nonoperating Income	106,737	882	160,560	1,673
Net loss	$ (1,606,254)	$ (687,089)	$ (3,724,739)	$ (1,278,456)
Earnings Per Share, Diluted	$ (0.23)	$ (0.12)	$ (0.53)	$ (0.28)
Earnings Per Share, Basic	$ (0.23)	$ (0.12)	$ (0.53)	$ (0.28)
Loss from operations	$ (1,712,991)	$ (687,971)	$ (3,885,299)	$ (1,280,129)
Operating expenses:
Research and development	1,074,954	724,556	2,701,330	1,599,358
Sales and marketing	810,209	442,230	2,235,646	1,105,548
General and administrative	1,102,260	965,711	3,468,452	3,254,210
Total operating expenses	2,987,423	2,132,497	8,405,428	5,959,116
Gross profit	1,274,432	1,444,526	4,520,129	4,678,987
Cost of revenues	$ 693,571	$ 619,833	$ 1,888,566	$ 1,754,343

Equity Rollforward Statement

Equity Rollforward Statement - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Preferred Stock Convertible Preferred Stock [Member]	Common Stock [Member]
Stockholders' Equity Attributable to Parent	$ 5,247,775		$ 202,129,194	$ (196,881,800)	$ 1	$ 380
Shares, Outstanding					200	3,807,555
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	68,863		68,863
Stock Issued During Period, Shares, New Issues		2,408
Stock Issued During Period, Value, New Issues	4,197	$ 1	4,196
Net Income (Loss) Attributable to Parent	(59,783)			(59,783)
Net Income (Loss) Attributable to Parent	(1,278,456)
Stockholders' Equity Attributable to Parent	5,261,052		202,202,253	(196,941,583)	$ 1	$ 381
Shares, Outstanding					200	3,809,963
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	319,863		319,863
Stock Issued During Period, Shares, New Issues		1,207,681
Stock Issued During Period, Value, New Issues	3,766,848	$ 121	3,766,727
Stock Issued During Period, Shares, Employee Stock Purchase Plans		7,055
Stock Issued During Period, Value, Employee Stock Purchase Plan	18,950	$ 1	18,949
Stock Issued During Period, Value, Restricted Stock Award, Gross		$ (3)	3
Stock Issued During Period, Shares, Restricted Stock Award, Gross		13,911
Net Income (Loss) Attributable to Parent	(531,584)			(531,584)
Stockholders' Equity Attributable to Parent	8,835,129		206,307,789	(197,473,167)	$ 1	$ 506
Shares, Outstanding					200	5,038,610
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	196,361		196,361
Stock Issued During Period, Shares, New Issues		1,549,024
Stock Issued During Period, Value, New Issues	15,805,110	$ 154	15,804,956
Stock Issued During Period, Value, Stock Options Exercised	78,500	$ 5	78,495
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period		50,000
Stock Issued During Period, Value, Restricted Stock Award, Gross		$ (1)	1
Stock Issued During Period, Shares, Restricted Stock Award, Gross		10,877
Net Income (Loss) Attributable to Parent	(687,089)			(687,089)
Stockholders' Equity Attributable to Parent	24,228,011		222,387,600	(198,160,256)	$ 1	$ 666
Shares, Outstanding					200	6,648,511
Stockholders' Equity Attributable to Parent	23,215,786		222,378,373	(199,163,257)	$ 1	$ 669
Shares, Outstanding					200	6,664,296
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	37,632		37,632
Stock Issued During Period, Shares, New Issues		292,500
Stock Issued During Period, Value, New Issues	1,943,052	$ 29	1,943,023
Stock Issued During Period, Value, Restricted Stock Award, Gross		$ (3)	3
Stock Issued During Period, Shares, Restricted Stock Award, Gross		1,759
Net Income (Loss) Attributable to Parent	(958,562)			(958,562)
Net Income (Loss) Attributable to Parent	(3,724,739)
Stockholders' Equity Attributable to Parent	24,237,908		224,359,025	(200,121,819)	$ 1	$ 701
Shares, Outstanding					200	6,958,555
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	109,340		109,340
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		50,213
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	215,417	$ 5	215,412
Stock Issued During Period, Shares, Employee Stock Purchase Plans		2,503
Stock Issued During Period, Value, Employee Stock Purchase Plan	7,829		7,829
Stock Issued During Period, Value, Restricted Stock Award, Gross		$ (7)	(7)
Stock Issued During Period, Shares, Restricted Stock Award, Gross		3,120
Net Income (Loss) Attributable to Parent	(1,159,923)			(1,159,923)
Stockholders' Equity Attributable to Parent	23,410,571		224,691,599	(201,281,742)	$ 1	$ 713
Shares, Outstanding					200	7,014,391
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	161,951		161,951
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ (202,008)	$ (1)	(1)
Stock Issued During Period, Shares, Restricted Stock Award, Gross	57,972	16,578
Net Income (Loss) Attributable to Parent	$ (1,606,254)			(1,606,254)
Stockholders' Equity Attributable to Parent	$ 21,966,268		$ 224,853,549	$ (202,887,996)	$ 1	$ 714
Shares, Outstanding					200	7,030,969

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Statement of Cash Flows [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ (3,724,739)	$ (1,278,456)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	39,170	103,594
Stock-based compensation	308,923	585,087
CompensationObligationSettlement	26,019	0
IdleFacilityImpairmentCharge	0	126,748
Changes in operating assets and liabilities:
Accounts receivable	(391,641)	(305,469)
Inventories	(350,686)	54,331
Prepaid expenses and other current and long-term assets	(383,310)	(612,661)
Accounts payable	255,343	174,653
Accrued expenses and compensation	569,902	89,931
Increase (Decrease) in Accrued Product Returns	(29,000)	(499,000)
Net Cash Provided by (Used in) Operating Activities	(3,806,422)	(1,561,242)
Payments to Acquire Held-to-maturity Securities	(18,921,376)	0
Cash flows from investing activities:
Purchases of fixed assets	(23,182)	(125,039)
Net Cash Provided by (Used in) Investing Activities	(18,944,558)	(125,039)
Cash flows from financing activities:
Net proceeds from issuance of stock and warrants	1,950,881	19,673,605
Net Cash Provided by (Used in) Financing Activities	1,950,881	19,673,605
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(20,800,099)	17,987,324
Cash and cash equivalents, end of period	1,772,005
Supplemental disclosure of cash flow information:
Stock Issuance Settle Incentive Compensation Obligation	189,398	0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	1,772,005	23,213,537
Gain (Loss) on Disposition of Property Plant Equipment	6,875	0
Interest Income Accretion Held To Maturity Securities	$ (133,278)	$ 0

Business and Basis of Presentat

Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Our Business-An Overview NeuroMetrix, Inc. (the "Company" or "NeuroMetrix") develops and commercializes health care products that utilize non-invasive neurostimulation. Revenues are derived from the sale of medical devices and after-market consumable products and accessories. The Company’s products are sold in the United States and select overseas markets. They are cleared by the U.S. Food and Drug Administration ("FDA") and regulators in foreign jurisdictions where appropriate. The Company has two primary products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. Quell ® is a wearable neuromodulation technology indicated for treatment of fibromyalgia symptoms and chronic lower extremity pain. The Company held cash, cash equivalents and held-to-maturity securities totaling $20.8 million as of September 30, 2022. The Company has a history of operating losses and has financed its operations primarily from sales of equity, sales of its products and third party development collaboration payments. The Company believes that its present balance of cash and held-to-maturity securities resources coupled with cash inflows from product sales will enable the Company to fund its operations for at least the next twelve months from the date of issuance of the financial statements. Actual cash requirements could differ from management's projections for many reasons. These include the effects of the Covid-19 pandemic on sales, procurement of production materials, and maintenance of critical staffing. They could also include changes the Company may make to its business strategy that affect operating expenses, regulatory developments, changes to research and development spending plans; and other items affecting the Company's projected uses of cash. Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of September 30, 2022, unaudited statements of operations, changes in stockholders' equity for the quarters and nine months ended September 30, 2022 and 2021 and cash flows for the nine months ended September 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2021 does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on January 28, 2022 (File No. 001-33351). Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Accrued product returns are estimated based on historical data and evaluation of current information. Accounts receivable are recorded at the amount the Company expects to collect, net of the allowance for doubtful accounts receivable. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses based on customer past payment history, product usage activity, and recent communications with the customer. Individual customer balances which are over 90 days past due are reviewed individually for collectability and written-off when recovery is not probable. Allowance for doubtful accounts was $25,000 as of September 30, 2022 and December 31, 2021. Two customers accounted for 32% and one customer accounted for 34% of total revenues in the quarter and nine months ended September 30, 2022, respectively. One customer accounted for 25% and 29% of total revenues in the quarter and nine months ended September 30, 2021, respectively. One customer accounted for 26% and two customers accounted for 35% of accounts receivable as of September 30, 2022 and December 31, 2021, respectively. Held-To-Maturity Securities The Company's investments in held-to-maturity securities consist of investment grade U.S. Treasury obligations, commercial paper and corporate bonds with maturity dates of less than 365 days. The Company has the ability and intention to hold these securities until maturity. Accordingly, these securities are recorded in the Company's balance sheet at amortized cost and interest is recorded within other income on the Company's statement of operations. The market value of the held-to-maturity securities at September 30, 2022 was $18,937,643. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.

Comprehensive Loss

Comprehensive Loss	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Comprehensive Loss	Comprehensive Loss For the quarters and nine months ended September 30, 2022 and 2021, the Company had no components of other comprehensive loss other than net loss itself.

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Common Share	Net Loss Per Common Share Basic and dilutive net loss per common share were as follows: Quarters Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net loss applicable to common stockholders $ (1,606,254) $ (687,089) $ (3,724,739) $ (1,278,456) Weighted average number of common shares outstanding, basic and dilutive 7,025,254 5,818,449 6,976,548 4,597,580 Net loss per common share applicable to common stockholders, basic and diluted $ (0.23) $ (0.12) $ (0.53) $ (0.28) Shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented: September 30, 2022 2021 Options 525,468 504,045 Unvested restricted stock awards 106,550 10,702 Unvested restricted stock units 207,233 — Convertible preferred stock 62 62 Total 839,313 514,809
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarters Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net loss applicable to common stockholders $ (1,606,254) $ (687,089) $ (3,724,739) $ (1,278,456) Weighted average number of common shares outstanding, basic and dilutive 7,025,254 5,818,449 6,976,548 4,597,580 Net loss per common share applicable to common stockholders, basic and diluted $ (0.23) $ (0.12) $ (0.53) $ (0.28)

Inventories

Inventories	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: September 30, 2022 December 31, 2021 Purchased components $ 461,349 $ 422,093 Finished goods 595,890 284,460 $ 1,057,239 $ 706,553

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses and Compensation Accrued expenses and compensation consist of the following: September 30, 2022 December 31, 2021 Professional services $ 277,000 $ 109,000 Compensation 522,044 440,474 Consulting 125,000 5,000 Warranty 18,000 28,400 Leasehold — 60,000 Sales tax 143,136 108,788 Other 49,479 62,493 $ 1,134,659 $ 814,155

Leases Leases (Notes)

Leases Leases (Notes)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Lessee, Operating Leases [Text Block]	Operating Leases The Company's lease on its Woburn, Massachusetts corporate office and manufacturing facility extends through September 2025 with a monthly base rent of $13,846 and a 5-year extension option. Future minimum lease payments under this non-cancellable operating lease as of September 30, 2022 are as follows: 2022 $ 41,446 2023 165,785 2024 165,785 2025 117,431 Total minimum lease payments $ 490,447 Discount rate, 15% $ 108,363 Lease obligation, current portion 148,391 Lease obligation, net of current portion 233,693 $ 490,447 The Company's lease on its former corporate office in Waltham, Massachusetts expired in February 2022. During the first quarter of 2021, the Company recorded an impairment charge of $126,748 on that idle facility which was being offered for sublet. In the first quarter of 2022, a $60,000 reduction in rent expense was recorded upon return of the facility to the lessor. The letter of credit issued by a bank in favor of the Waltham facility was released. For the nine months ended September 30, 2022, the Company recorded sublet income totaling $22,795 within operating expenses on the Company's statement of operations.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Assets and liabilities that are measured at fair value are presented below. All Company assets and liabilities measured at fair value utilize Level 1 inputs (i.e. quoted prices (unadjusted) in active markets for identical assets or liabilities). Fair Value Measurements at September 30, 2022 Using September 30, 2022 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 1,230,690 $ 1,230,690 $ — $ — Total $ 1,230,690 $ 1,230,690 $ — $ — Fair Value Measurements at December 31, 2021 Using December 31, 2021 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 20,317,736 $ 20,317,736 $ — $ — Total $ 20,317,736 $ 20,317,736 $ — $ —

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred stock and convertible preferred stock consist of the following: September 30, 2022 December 31, 2021 Preferred stock, $0.001 par value; 5,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at September 30, 2022 and December 31, 2021; 200 shares issued and outstanding at September 30, 2022 and December 31, 2021 $ 1 $ 1 2022 equity activity In January 2022, the Company issued 292,500 shares of common stock under an at-the-market (ATM) equity offering program with net proceeds of $1,943,052 and issued 20,000 restricted stock awards under its 2004 Stock Option Plan with a value of $104,200. In April 2022, the Company issued 76,000 shares of restricted common stock under its 2022 Equity Incentive Plan with a value of $326,000 to employees as long term incentives (LTI) and issued 50,213 shares of fully vested common stock with a value of $215,417 in settlement of management incentive compensation. In May 2022, the Company issued 161,764 restricted stock units with a value of $550,000 as LTI to its management and directors under its 2022 Equity Incentive Plan. In June 2022, the Company issued 2,503 shares of fully vested common stock with a value of $7,829 pursuant to the Company's Employee Stock Purchase Plan. For the quarter ended September 30, 2022, the Company issued 57,972 restricted stock units with a value of $202,008 under its 2022 Equity Incentive Plan. As of September 30, 2022, the Company had 106,550 unvested shares of restricted common stock and 207,233 unvested restricted stock units. Total compensation cost related to non-vested awards not yet recognized at September 30, 2022 was $1,224,278. These unrecognized costs are expected to be recognized over a weighted-average period of 2.3 years. Subsequently from October 1, 2022 to October 19, 2022 the Company issued 623,834 shares of Common Stock under its ATM program with net proceeds of $1,890,721. 2021 equity activity

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of September 30, 2022, unaudited statements of operations, changes in stockholders' equity for the quarters and nine months ended September 30, 2022 and 2021 and cash flows for the nine months ended September 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2021 does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on January 28, 2022 (File No. 001-33351).
Revenues	Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Accrued product returns are estimated based on historical data and evaluation of current information. Accounts receivable are recorded at the amount the Company expects to collect, net of the allowance for doubtful accounts receivable. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses based on customer past payment history, product usage activity, and recent communications with the customer. Individual customer balances which are over 90 days past due are reviewed individually for collectability and written-off when recovery is not probable. Allowance for doubtful accounts was $25,000 as of September 30, 2022 and December 31, 2021.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.
Marketable Securities, Policy	Held-To-Maturity Securities The Company's investments in held-to-maturity securities consist of investment grade U.S. Treasury obligations, commercial paper and corporate bonds with maturity dates of less than 365 days. The Company has the ability and intention to hold these securities until maturity. Accordingly, these securities are recorded in the Company's balance sheet at amortized cost and interest is recorded within other income on the Company's statement of operations. The market value of the held-to-maturity securities at September 30, 2022 was $18,937,643.

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarters Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net loss applicable to common stockholders $ (1,606,254) $ (687,089) $ (3,724,739) $ (1,278,456) Weighted average number of common shares outstanding, basic and dilutive 7,025,254 5,818,449 6,976,548 4,597,580 Net loss per common share applicable to common stockholders, basic and diluted $ (0.23) $ (0.12) $ (0.53) $ (0.28)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	September 30, 2022 2021 Options 525,468 504,045 Unvested restricted stock awards 106,550 10,702 Unvested restricted stock units 207,233 — Convertible preferred stock 62 62 Total 839,313 514,809

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: September 30, 2022 December 31, 2021 Purchased components $ 461,349 $ 422,093 Finished goods 595,890 284,460 $ 1,057,239 $ 706,553

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses and compensation consist of the following: September 30, 2022 December 31, 2021 Professional services $ 277,000 $ 109,000 Compensation 522,044 440,474 Consulting 125,000 5,000 Warranty 18,000 28,400 Leasehold — 60,000 Sales tax 143,136 108,788 Other 49,479 62,493 $ 1,134,659 $ 814,155

Leases Leases (Tables)

Leases Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2022 $ 41,446 2023 165,785 2024 165,785 2025 117,431 Total minimum lease payments $ 490,447 Discount rate, 15% $ 108,363 Lease obligation, current portion 148,391 Lease obligation, net of current portion 233,693 $ 490,447

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Fair Value Measurements at September 30, 2022 Using September 30, 2022 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 1,230,690 $ 1,230,690 $ — $ — Total $ 1,230,690 $ 1,230,690 $ — $ — Fair Value Measurements at December 31, 2021 Using December 31, 2021 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 20,317,736 $ 20,317,736 $ — $ — Total $ 20,317,736 $ 20,317,736 $ — $ —

Statement of Shareholders' Equi

Statement of Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Stock by Class [Table Text Block]	Preferred stock and convertible preferred stock consist of the following: September 30, 2022 December 31, 2021 Preferred stock, $0.001 par value; 5,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at September 30, 2022 and December 31, 2021; 200 shares issued and outstanding at September 30, 2022 and December 31, 2021 $ 1 $ 1

Business and Basis of Present_3

Business and Basis of Presentation (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Organization And Basis Of Presentation [Line Items]
Accounts receivable, net	$ 702,459		$ 702,459		$ 310,818
Net proceeds from issuance of stock and warrants			1,950,881	$ 19,673,605
Accumulated deficit	202,887,996		202,887,996		199,163,257
Cash and cash equivalents	1,772,005		1,772,005		22,572,104
Prepaid expenses and other current assets	(845,649)		(845,649)		(598,384)
Assets, Current	(23,432,006)		(23,432,006)		(24,187,859)
Accrued Sales Return provisions	10,000		10,000		39,000
Liabilities, Current	(1,832,429)		(1,832,429)		(1,365,697)
Operating Lease, Liability, Noncurrent	(233,693)		(233,693)		(306,709)
Stockholders' Equity Attributable to Parent	21,966,268	$ 24,228,011	21,966,268	24,228,011	23,215,786	$ 23,410,571	$ 24,237,908	$ 8,835,129	$ 5,261,052	$ 5,247,775
Cost of revenues	693,571	619,833	1,888,566	1,754,343
Gross Profit	1,274,432	1,444,526	4,520,129	4,678,987
Compensation cost not yet recognized	1,224,278		1,224,278
Operating Lease, Right-of-Use Asset	(398,144)		(398,144)		(475,230)
Assets	(24,032,390)		(24,032,390)		(24,888,192)
Accrued Liabilities, Current	(1,134,659)		(1,134,659)		(814,155)
Liabilities	(2,066,122)		(2,066,122)		(1,672,406)
Allowance for doubtful accounts	25,000		25,000		$ 25,000
Other Comprehensive Income (Loss), Net of Tax	0	$ 0	0	0
IdleFacilityImpairmentCharge			0	$ 126,748
Cash, Cash Equivalents, and Short-term Investments	20,800,000		20,800,000
Debt Securities, Held-to-maturity, Fair Value	$ 18,937,643		$ 18,937,643
One Customer | Revenue | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage		25%	34%	29%
One Customer | Accounts Receivable | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage			26%
Two Customers | Revenue | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage	32%
Two Customers | Accounts Receivable | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage					35%

Comprehensive Loss (Detail)

Comprehensive Loss (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Equity [Abstract]
Other Comprehensive Income (Loss), Net of Tax	$ 0	$ 0	$ 0	$ 0

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	839,313	514,809
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	62	62
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	525,468	504,045
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	106,550	10,702
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	207,233	0

Net Loss Per Common Share Sched

Net Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Income (Loss) Attributable to Parent	$ (1,606,254)	$ (1,159,923)	$ (958,562)	$ (687,089)	$ (531,584)	$ (59,783)	$ (3,724,739)	$ (1,278,456)
Weighted Average Number of Shares Outstanding, Basic	7,025,254			5,818,449			6,976,548	4,597,580
Weighted Average Number of Shares Outstanding, Diluted	7,025,254			5,818,449			6,976,548	4,597,580
Earnings Per Share, Diluted	$ (0.23)			$ (0.12)			$ (0.53)	$ (0.28)
Earnings Per Share, Basic	$ (0.23)			$ (0.12)			$ (0.53)	$ (0.28)

Inventories (Detail)

Inventories (Detail) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Inventory [Line Items]
Purchased components	$ 461,349	$ 422,093
Finished goods	595,890	284,460
Inventories	$ 1,057,239	$ 706,553

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Sales return allowance	$ 10,000	$ 39,000
Accrued Leaseholds Current	0	60,000
Professional services	277,000	109,000
Accrued Salaries, Current	522,044	440,474
Accrued Consulting Current	125,000	5,000
Warranty reserve	18,000	28,400
Other	49,479	62,493
Sales and Excise Tax Payable, Current	143,136	108,788
Accrued expenses	$ 1,134,659	$ 814,155

Leases Leases (Details)

Leases Leases (Details) - USD ($)		3 Months Ended				9 Months Ended
	Jun. 01, 2018	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Operating Leased Assets [Line Items]
Operating Lease, Weighted Average Discount Rate, Percent		15%				15%
Operating Lease, Weighted Average Remaining Lease Term		3 years				3 years
IdleFacilityImpairmentCharge						$ 0	$ 126,748
Operating Lease, Expense		$ 46,102		$ 18,932		116,959	$ 243,289
Operating Lease, Right-of-Use Asset		398,144				398,144		$ 475,230
Lessee, Operating Lease, Liability, to be Paid, Year One		41,446				41,446
Lessee, Operating Lease, Liability, to be Paid, Year Two		165,785				165,785
Lessee, Operating Lease, Liability, to be Paid, Year Three		165,785				165,785
Lessee, Operating Lease, Liability, to be Paid, Year Four		117,431				117,431
Lessee, Operating Lease, Liability, to be Paid		490,447				490,447
Operating Lease Discount		108,363				108,363
Operating Lease, Liability, Current		148,391				148,391		228,506
Operating Lease, Liability, Noncurrent		$ 233,693				233,693		$ 306,709
Rent Expense Reduction			$ 60,000
Sublease Income						$ 22,795
Woburn Lease [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Renewal Term	5 years
Woburn Lease [Member] | MonthlyRent [Member]
Operating Leased Assets [Line Items]
Operating Lease, Payments	$ 13,846
Waltham Lease [Member] | Idle Facility Impairment [Member]
Operating Leased Assets [Line Items]
Restructuring Charges					$ 126,748
Restructuring Charges					$ 126,748

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Assets
Cash equivalents	$ 1,230,690	$ 20,317,736
Assets, Fair Value Disclosure	1,230,690	20,317,736
Level 1
Assets
Cash equivalents	1,230,690	20,317,736
Assets, Fair Value Disclosure	1,230,690	20,317,736
Level 2
Assets
Cash equivalents	0	0
Assets, Fair Value Disclosure	0	0
Level 3
Assets
Cash equivalents	0	0
Assets, Fair Value Disclosure	$ 0	$ 0

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended									3 Months Ended						5 Months Ended	9 Months Ended
	Oct. 19, 2022	Jun. 30, 2022	May 31, 2022	Apr. 30, 2022	Jan. 31, 2022	Aug. 31, 2021	Jun. 30, 2021	May 31, 2021	Jan. 31, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Class of Stock [Line Items]
Stock Issued During Period, Value, Employee Stock Purchase Plan							$ 18,950				$ 7,829			$ 18,950
Net proceeds from issuance of stock and warrants																	$ 1,950,881	$ 19,673,605
Common stock, par value (in dollars per share)										$ 0.0001							$ 0.0001		$ 0.0001
Compensation cost not yet recognized										$ 1,224,278							$ 1,224,278
Compensation cost not yet recognized, period for recognition																	2 years 3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number													10,702			10,702		10,702
Stock Issued During Period, Shares, Restricted Stock Award, Gross			161,764	76,000						57,972
Stock Issued During Period, Value, Restricted Stock Award, Gross			$ 550,000	$ 326,000						$ 202,008
Stock Issued During Period, Value, New Issues												$ 1,943,052	$ 15,805,110	$ 3,766,848	$ 4,197
Stock Issued During Period, Value, Stock Options Exercised													$ 78,500
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans		2,503					7,055		2,408		2,503			7,055
Stock Issued During Period, Value, Employee Stock Purchase Plan		$ 7,829							$ 4,197					$ 1
Stock Issued During Period, Shares, New Issues												292,500	1,549,024	1,207,681	2,408
Stock Issued During Period, Shares, Restricted Stock Award, Gross					20,000			42,808		16,578	3,120	1,759	10,877	13,911
Stock Issued During Period, Value, Restricted Stock Award, Gross					$ 104,200			$ 125,000		$ 1	$ 7	$ 3	$ 1	$ 3
Stock Issued During Period, Value, New Issues												$ 29	$ 154	$ 121	$ 1
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period						50,000							50,000
Stock Issued During Period, Value, Stock Options Exercised						$ 78,500							$ 5
Restricted Stock
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number										106,550							106,550
Restricted Stock | Common Stock [Member]
Class of Stock [Line Items]
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation																7,318
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period																24,788
Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number										207,233							207,233
Management Incentive Compensation | Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues				50,213
Stock Issued During Period, Value, New Issues				$ 215,417
At The Market Offering Program [Member]
Class of Stock [Line Items]
Proceeds from Issuance of Common Stock																		$ 19,571,958
At The Market Offering Program [Member] | Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues					292,500													2,756,705
Proceeds from Issuance of Common Stock					$ 1,943,052
At The Market Offering Program [Member] | Common Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	623,834
Proceeds from Issuance of Common Stock	$ 1,890,721

Preferred Stock and Convertible

Preferred Stock and Convertible Preferred Stock (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Preferred Non-Convertible Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Value of preferred stock issued	$ 0	$ 0
Preferred stock, shares outstanding (in shares)	0	0
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	147,000	147,000
Preferred stock, shares issued (in shares)	200	200
Value of preferred stock issued	$ 1	$ 1
Preferred stock, shares outstanding (in shares)	200	200

Uncategorized Items - nuro-2022

Label	Element	Value
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 22,572,104
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 5,226,213